Safety and efficacy of Adct-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma: interim results from the phase 1 first-in-human study
Caimi, P Kahl, S Hamadani, M Carlo-Stella, C He, S Ungar, D Feingold, J Ardeshna, M Radford, John A Solh, M
Caimi, P
Kahl, S
Hamadani, M
Carlo-Stella, C
He, S
Ungar, D
Feingold, J
Ardeshna, M
Radford, John A
Solh, M
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Caimi P, Kahl B, Hamadani M, Carlo-Stella C, He S, Ungar D, et al. Safety and efficacy of Adct-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed/refractory follicular lymphoma and mantle cell lymphoma: interim results from the phase 1 first-in-human study. Blood. 2018;132.